DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer

SHANGHAI, April 9, 2026 /PRNewswire/ — DualityBio ("DualityBio" or the "Company", Stock…

Terra Quantum AG to go public in $3.25 billion SPAC deal

Strategic go-public transaction aims to accelerate growth in quantum technologies and expand…

Businesses face sustained pressure in 2026 as global insolvencies rise 3%, Atradius forecasts

AMSTERDAM, April 9, 2026 /PRNewswire/ — Atradius forecasts a further rise in…

Phemex TradFi Crude Oil Trading Surges 300% as Ceasefire Volatility Sparks Record Demand

APIA, Samoa, April 9, 2026 /PRNewswire/ — Phemex, a user-first crypto exchange, reported…

OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease

ROCKVILLE, Md., April 9, 2026 /PRNewswire/ — OncoC4 Inc., a late clinical stage…

Exito Media Concepts Announces the 34th Edition of the BFSI IT Summit Indonesia 2026

Tech it to the Next Level: Shaping the Future of Indonesia’s BFSI…

Hong Kong Anti-graft Watchdog: Clean Governance and Ethical Business is Key to Hong Kong's Sustainable Business Development

HONG KONG, April 9, 2026 /PRNewswire/ — Hong Kong has long been recognised…

Kelun-Biotech Approved by HKEX to Remove "B" Marker from Stock Code, Representing a New Stage of Development

CHENGDU, China, April 9, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.…